Adeno-Associated Virus Gene Therapy for Hemophilia.

Adeno-Associated Virus Gene Therapy for Hemophilia.
复制标题

DOI:
10.1146/annurev-med-043021-033013
复制
发表时间:
2023-01-27
影响因子:
10.5
通讯作者:
--
中科院分区:
医学1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

体内基因治疗正迅速成为单基因疾病的一种新的治疗范式。近三十年来,血友病A (HA)和血友病B (HB)一直是基因治疗发展的模型疾病。随着关键腺相关病毒(AAV)载体基因添加试验的完成,这项努力很快就会取得成果,报告了令人鼓舞的结果,并广泛预期在不久的将来,当前一代HA和HB AAV载体将获得监管部门的批准。在这里,我们回顾了AAV基因治疗HA和HB的临床发展,并检查了最近在血友病和其他单基因疾病的AAV临床试验中出现的突出问题。
In vivo gene therapy is rapidly emerging as a new therapeutic paradigm for monogenic disorders. For almost three decades, hemophilia A (HA) and hemophilia B (HB) have served as model disorders for the development of gene therapy This effort is soon to bear fruit with completed pivotal adeno-associated viral (AAV) vector gene addition trials reporting encouraging results and regulatory approval widely anticipated in the near future for the current generation of HA and HB AAV vectors. Here we review the clinical development of AAV gene therapy for HA and HB and examine outstanding questions that have recently emerged from AAV clinical trials for hemophilia and other monogenic disorders.
DOI: 10.1172/jci79213
发表时间: 2015-02-01
影响因子: 15.9
作者:
Chandler, Randy J.;LaFave, Matthew C.;Venditti, Charles P.
通讯作者: Venditti, Charles P.
DOI: 10.1182/blood-2014-07-588194
发表时间: 2015-03-05
期刊: BLOOD
影响因子: 20.3
作者:
Crudele, Julie M.;Finn, Jonathan D.;Arruda, Valder R.
通讯作者: Arruda, Valder R.
DOI: 10.1182/blood-2017-08-742312
发表时间: 2017-11-23
期刊: BLOOD
影响因子: 20.3
作者:
Arruda, Valder R.;Doshi, Bhavya S.;Samelson-Jones, Benjamin J.
通讯作者: Samelson-Jones, Benjamin J.
DOI: 10.1038/gt.2017.95
发表时间: 2017-12
期刊: Gene therapy
影响因子: 5.1
作者:
Falese L;Sandza K;Yates B;Triffault S;Gangar S;Long B;Tsuruda L;Carter B;Vettermann C;Zoog SJ;Fong S
通讯作者: Fong S
DOI: 10.1182/blood-2010-06-293308
发表时间: 2010-12-23
期刊: BLOOD
影响因子: 20.3
作者:
Greene, Teshell K.;Wang, Cheng;Poncz, Mortimer
通讯作者: Poncz, Mortimer